VIC3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (COMPLETED)

NCT05991388

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

NCT05843253

Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant (CONNECT-TarGeT-A)

NCT05826535

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (LYL314-101)

NCT05533775

A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)

NCT05504291

Intravitreal Melphalan for Intraocular Retinoblastoma (ARET2121)

VIC3052 - Parkville - Royal Children's Hospital Melbourne (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT05417594

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

NCT05304585

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (ARST2032)

NCT05139017

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (2140-003)

NCT04989803

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (PALISADES-1)

NCT04684368

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (ACNS2021)

NCT04625907

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04332822

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (POLAR-BEAR)

NCT04322318

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (AREN1921)

NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)2305 - New Lambton Heights - John Hunter Children's Hospital (SUSPENDED)

3168 - Clayton - Monash Medical Centre (SUSPENDED)

SA5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)

NCT04221035

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04031677

A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) (STRASS2)

NCT03970447

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM-AGILE)

NCT03959085

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (AALL1732)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

NCT03666000

A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (PBCAR0191-01)

ACTRN12626000036314

To determine whether hypofractionated radiotherapy (HF-RT) combined with concurrent and adjuvant temozolomide (TMZ) provides survival outcomes that are not inferior to those of conventional fractionated radiotherapy (CF-RT) with concurrent and adjuvant TMZ in adults with newly diagnosed Grade 4 Glioblastoma (CONCISE)

ACTRN12625001031459

Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.

ACTRN12625001003460

ALLG AMLM29 CAVIAT-R (Combining Anti-BCL2 and intensive chemotherapy in Acute Myeloid Leukaemia (AML) Trial- Randomised) : a multicentre phase III trial for newly diagnosed AML

ACTRN12625000965404

ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (CLL-RT2)

ACTRN12624001484538

Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM). (GBMI12)

ACTRN12624001142527

Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (nil)

ACTRN12624000110583

Not Applicable

SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (SOCRATES-PILOT)

ACTRN12623001301651

Not Applicable

GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients (GeneScreen-5-FU)

ACTRN12622001366741

Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial

ACTRN12622001232729

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (The-ANZHIT-2-study)

ACTRN12622000675729

Not Applicable

A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma (LEVI’S-CATCH)

ACTRN12622000308796

A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (VICTORY-study)

ACTRN12621000802808

A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults. (LU-TEMP)

ACTRN12619000079145

A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The-AutoCAR19-Trial)

ACTRN12613001154796

A phase 2 trial of cyclophosphamide as prophylaxis for graft-versus-host disease after HLA-identical allogeneic donor transplantation using reduced intensity conditioning therapy (PT-CYCLO)

ACTRN12612001050842

Valproate and MetformIn in GlioBlastoma multiformE Study: A single-arm trial to assess safety and feasibility – VIBE 1

ACTRN12610000440022

CLEMENT Capecitabine-radiosensitizing Lutetium-177 octreotate endoradiotherapy management of endocrine neurogenic tumours Response and Toxicity Assessment

ACTRN12609000997257

Busilvex plus Fludarabine Vs Busilvex plus Cyclophosphamide prior allogeneic transplantation in Acure Myeloid Leukimia (AML) to evaluate the transplant-related mortality. (GITMO)

ACTRN12609000504213

Not Applicable

Cardiac monitoring with echocardiogram and tissue doppler imaging (TDI) and serum biomarkers to assess for cardiotoxicity with anthracyclines in women during adjuvant chemotherapy for breast cancer. (ECHO)

ACTRN12609000260224

In patients with malignant mesothelioma (MM) and non-small cell lung cancer (NSCLC) does low-dose iterative cyclophosphamide in combination with conventionally dosed pemetrexed-based chemotherapy decrease regulatory T cell numbers and increase antigen-specific and non-specific cellular immunity. (No)

ACTRN12608000129381

Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse

ACTRN12608000013369

Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response

ACTRN12606000433505

A Three-Stage Phase I/II Dose-Escalation Study of High-Dose Melphalan with Palifermin for Patients with Multiple Myeloma to Determine a New Maximum Tolerated Dose (MTD) of Melphalan for use in Autografting (ALLG)

ACTRN12606000030572

An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer (ACCELERATE)

ACTRN12605000731695

Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer

ACTRN12605000377639

A randomised phase II study comparing the safety and efficacy of capecitabine with capecitabine and oral cyclophosphamide in patients with advanced breast cancer (Cyclox-II)

CD20	18%
CD19	15%
PD-1/PD-L1	7%
KIT	7%
cereblon	5%
proteasome	5%
VEGFR2	5%
PD-1	5%
RET	5%
VEGF	5%
VEGFR	5%
BTK	5%
Bcl2	5%
AXL	4%
HIF2a	4%
MET	4%
ROS1	4%
GD2	4%
PARP	4%
Trop2	4%
PI3K delta	4%
mTOR	4%
mTORC1	4%
CD38	3%
MER	3%
BCMA	3%
LAG3	3%
ROR1	3%
PI3K	3%
PI3Kalpha	3%
mTORC2	3%
CDK4	3%
CDK6	3%
FGFR	3%
FGFR1	3%
FGFR1/2/3	3%
FGFR2	3%
FGFR3	3%
FGFR4	3%
PDGFR	3%
IL-2	1%
PD-L1	1%
GPRC5D	1%
ALK	1%
DPD	1%
orotate phosphoribosyltransferase	1%
B7H3	1%
IDH1	1%
IDH1 R132	1%
BCR-ABL1	1%
PDGFRA	1%
SRC	1%
YES1	1%
IL-6	1%
ERBB2	1%
PARP1-selective	1%
CD79b	1%
ATM	1%
CD22	1%
AR	1%
CYP17A1	1%
HMG-CoA reductase	1%
androgen axis	1%
oestrogen axis	1%
XPO1	1%
HDAC	1%

ARTICANZ - Beta (ver 0.91)

Search results

target/alkylating-agent

Filters